Bonnie Chen is a partner in the Intellectual Property & Technology Transactions Group. Bonnie focuses her practice on advising clients on a wide range of IP and technology-related corporate and commercial transactions, including intellectual property aspects of public and private mergers, acquisitions, joint ventures, and carve-outs. She also advises on licensing and collaboration agreements, research and development agreements, supply agreements, distribution agreements and other strategic commercial agreements.
With a degree in biological engineering, Bonnie has extensive experience with advising clients in the pharmaceutical, biotechnology and medical device industries, including transactions involving small molecules, biologics, and gene therapies. Bonnie also has extensive experience with advising clients in the technology, media and telecommunications, financial institutions, retail and fashion industries.
In 2026, Bonnie was named to the IAM Patent 1000 and is recommended as Next Generation. Bonnie also was shortlisted for IFLR’s 2026 Women in Business Law Americas Award for Intellectual Property Rising Star and recognized in the WIPR 2026 “Leaders” list. Since 2024, Bonnie has been recognized as a "500 X – The Next Generation" lawyer by Lawdragon and was named in Lawdragon’s 500 Leading Global IP Lawyers guide. In 2024, Bonnie was named as part of the “IP Team of the Year” by Luxury Law, was shortlisted as an “Intellectual Property Rising Star" by Euromoney’s 2024 Women in Business Law Americas Awards.
Bonnie’s notable representations have included:
- GSK in its:
- acquisition of CMG1A46, an autoimmune disease treatment, from Chimagen Biosciences
- agreement with Duality Biologics that grants GSK an exclusive option to obtain an exclusive license to develop and commercialize an antibody-drug conjugate candidate
- Carrier Global Corporation in its:
- $3 billion sale of its commercial and residential fire business to an affiliate of Lone Star Funds
- €12 billion acquisition of Viessmann Climate Solution
- $4.95 billion sale of its global access solutions business to Honeywell
- $1.425 billion sale of its industrial fire business to Sentinel Capital Partners
- $775 million sale of its global commercial refrigeration business to Haier
- Merck in its $10.8 billion acquisition of Prometheus Biosciences
- Eli Lilly in:
- its up to $8.5 billion strategic collaboration with Innovent Biologics, a regular collaborator with Lilly, to advance novel medicines in oncology and immunology
- a strategic platform-based collaboration with Ailux, a wholly owned subsidiary of XtalPi, to advance bispecific antibody development
- its strategic research collaboration with Profluent, an AI-first company pioneering the use of large AI models for protein design
- its agreement with Insilico, a biotechnology company with a proprietary artificial intelligence drug discovery platform, to leverage Insilico’s platform in order to discover and develop products for the treatment of pathogens resistant to current antibiotics
- its global research collaboration and licensing agreement with biotechnology company Ascidian Therapeutics to discover and develop therapies for undisclosed monogenic kidney diseases
- The Estée Lauder Companies in its $2.8 billion acquisition of the Tom Ford brand
- PCI Pharma Services and Kohlberg, an existing lead investor in PCI, in PCI's strategic investment co-led by Bain Capital and Kohlberg and supported by Mubadala Investment Company
- Dana Incorporated in its approximately $2.7 billion sale of its off-highway business to Allison Transmission Holdings
- Funds managed by affiliates of Apollo Global Management in:
- an investment of $11 billion to acquire from Intel Corporation a 49% equity interest in a joint venture entity related to Intel’s Fab 34
- their ¥311 billion investment (approximately $2.05 billion) to acquire a majority stake in Panasonic Automotive Systems Co.
- Eaton Corporation in its:
- $9.5 billion acquisition of the Boyd Thermal business of Boyd Corporation
- acquisition of Resilient Power Systems
- planned separation of its Vehicle and eMobility segments into an independent, publicly traded company
- Galapagos in a research and development collaboration with Gilead in connection with Gilead’s $1.675 billion acquisition of Ouro Medicines
- Polaris in the separation of Indian Motorcycle and subsequent sale of a majority stake in the new company to Carolwood
- Fernando Chico Pardo and his family in their $2.3 billion acquisition of a 25% equity stake in Grupo Financiero Banamex from Citi
- Rodina Capital in its acquisition of Rubicon Technologies’ fleet technology business unit and convertible preferred equity
- Ashton Kutcher in his investment in Soho House & Co., in connection with Soho House's $2.7 billion take-private transaction
- General Electric in the spin-off of GE Vernova and the launch of GE Aerospace
- Fernando Chico Pardo and his family in their $2.3 billion acquisition of a 25% equity stake in Grupo Financiero Banamex
- 23andMe in voluntary chapter 11 proceedings in the U.S. Bankruptcy Court for the Eastern District of Missouri
- Polaris in the separation of Indian Motorcycle and subsequent sale of a majority stake in the new company to Carolwood
- AbbVie in its up to $212.5 million acquisition of Landos Biopharma
- IBM in its acquisition of NS1
Prior to joining Paul, Weiss, Bonnie’s various transactions include advising:
- GSK in its option and license agreement with Boston Pharmaceuticals
- Roche in its acquisitions of Flatiron Health and Tensha Therapeutics
- Bristol Myers Squibb in its acquisition of Forbius
- L Brands in its separation from Victoria’s Secret
- The Ferrero Group’s in its acquisition of Kellogg Company’s cookie, fruit and fruit-flavored snack, ice cream cone and pie crust businesses
- Novartis in its acquisition of worldwide rights for Fibroblast Activation Protein targeting agents from iTheranostics (an affiliate of SOFIE Biosciences)
- Comcast in its “put/call” agreement with The Walt Disney Company regarding NBCUniversal’s 33% ownership interest in Hulu
- AstraZeneca in its acquisition of ZS Pharma
- V.F. Corporation in its sale of its Contemporary Brands businesses to Delta Galil Industries
- Solvay in its buyout of its joint venture with Eastman Chemical Company
- Novo Nordisk in its acquisition of Emisphere Technologies
- Shire in its sale of its mRNA platform to Translate Bio and sale of its oncology business to Servier
- Roivant Sciences in its combination with a SPAC
- AC Immune in its collaboration with Eli Lilly
- BVF Partners LP in MoonLake Immunotherapeutics’ exclusive in-license of Sonelokimab from Merck KGaA
- Freeline Therapeutics in its commercial manufacturing arrangement with Brammer Bio
- AC Immune, ADC Therapeutics and Freeline Therapeutics in their IPOs
- The underwriters for Editas Medicine, Prime Medicine, Zai Labs and Denali Therapeutics in their IPOs
